Andris Gardovskis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andris Gardovskis has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Edvins Miklasevics
Faculty of Medicine, Riga Stradins University, LV-1007 Riga, Latvia
2 shared publications - Janis Gardovskis
Department of Surgery, Riga Stradins University, Dzirciema Street 16, LV-1007 Riga, Latvia
2 shared publications - Linda Kokaine
Pauls Stradinљ Clinical University Hospital, Department of Surgery, Riga, Latvia
2 shared publications - Zanda Daneberga
Institute of Oncology and Molecular Genetics, Rīga Stradiņš University, Riga, Latvia
2 shared publications - Dace Berzina
Institute of Oncology, Riga Stradins University, LV-1007 Riga, Latvia
1 shared publication - Daniella Zvina
Riga Stradins University, Latvia
1 shared publication
Latest Publications
- Open Access
- 13 January 2025
- Published by MDPI AG in Preprints.org
The Predictive Role of microRNA 142–5p, microRNA 182–3p, and microRNA 99a-3p in Disease-Free Survival and Overall Survival in Patients with Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy and Radical Surgery
Background/Objectives: MicroRNAs (miRNAs) are likely to play a significant role in the prediction of rectal cancer response to chemoradiation therapy, offering insights that complement other biological tumour markers. The study aimed to perform miRNA profiling in rectal cancer tissues in patients with good (GR) and bad response (BR) to neoadjuvant chemoradiation therapy (nCRT), select the potentially clinically relevant ones, and further evaluate their relationship with subsequent disease outcomes and survival prognosis. Methods: A total of 40 selected patients with locally advanced rectal cancer who received nCRT and following surgical treatment in the period from 2016 to 2021 were involved. Two study groups were created – GR and BR according to the Dworak tumour regression grading (TRG) system. The identification of 752 miRNAs was conducted in rectal cancer tissue. Results: Six upregulated miRNAs were set as clinically significant within the selected samples and subsequently validated in the BR and GR groups. MiR-142-5p, miR-182-3p, and miR-99a-3p exhibited statistical significance in validation. The results showed that BR to nCRT, lower expression of miRNA-142-5p and miR-99a-3p, and higher expression of miR-182-3p were associated with a trend toward worse local recurrence-free survival, distant metastases-free survival, and overall survival in comparison to GR. Conclusion: MiRNAs may potentially serve as clinical biomarkers in prediction of disease-free survival and overall survival in patients with rectal cancer.
- 13 January 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Predictive Role of microRNA 142–5p, microRNA 182–3p, and microRNA 99a-3p in Disease-Free Survival and Overall Survival in Patients with Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy and Radical Surgery
Background/Objectives: MicroRNAs (miRNAs) are likely to play a significant role in the prediction of rectal cancer response to chemoradiation therapy, offering insights that complement other biological tumour markers. The study aimed to perform miRNA profiling in rectal cancer tissues in patients with good (GR) and bad response (BR) to neoadjuvant chemoradiation therapy (nCRT), select the potentially clinically relevant ones, and further evaluate their relationship with subsequent disease outcomes and survival prognosis. Methods: A total of 40 selected patients with locally advanced rectal cancer who received nCRT and following surgical treatment in the period from 2016 to 2021 were involved. Two study groups were created – GR and BR according to the Dworak tumour regression grading (TRG) system. The identification of 752 miRNAs was conducted in rectal cancer tissue. Results: Six upregulated miRNAs were set as clinically significant within the selected samples and subsequently validated in the BR and GR groups. MiR-142-5p, miR-182-3p, and miR-99a-3p exhibited statistical significance in validation. The results showed that BR to nCRT, lower expression of miRNA-142-5p and miR-99a-3p, and higher expression of miR-182-3p were associated with a trend toward worse local recurrence-free survival, distant metastases-free survival, and overall survival in comparison to GR. Conclusion: MiRNAs may potentially serve as clinical biomarkers in prediction of disease-free survival and overall survival in patients with rectal cancer.
- Open Access
- 4 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 5119
Evaluation of Clinical Manifestations of Hemorrhoidal Disease, Carried Out Surgeries and Prolapsed Anorectal Tissues: Associations with ABO Blood Groups of Patients
Hemorrhoidal disease (HD) is a chronic multifactorial disease. Increased abdominal pressure, along with hyperperfusion, neovascularization, overexpression of inflammatory mediators, and dysbiosis, contributes to the development of HD. The deterioration of the anchoring connective tissue with reduced collagen content and altered collagen ratios, dilatation of blood vessels and thrombosis, muscle injury, and inflammation gradually lead to clinically manifesting prolapse and bleeding from hemorrhoids. The associations of the ABO blood types with a disease have been investigated for the upper gastrointestinal tract only. This study aimed to evaluate HD clinical manifestations, surgeries carried out, and the status of prolapsed anorectal tissues by exploring the associations with the patients’ ABO blood groups. Clinical and various morphological methods, combined with extensive bioinformatics, were used. The blood type 0, grade III and IV HD individuals constituted the largest group in a moderately-sized cohort of equally represented males and females studied and submitted to surgical treatment of hemorrhoids. There were significantly more complaints reported by HD females compared to males (p = 0.0094). The Longo technique appeared mostly used, and there were proportionally more surgeries performed below the dentate line for HD individuals with blood type 0 compared to other blood type patients (24% vs. 11%). HD males were found to present with significantly more often inflamed rectal mucosa (p < 0.05). Loosening and weakening of collagenous components of the rectal wall combined with vascular dilation and hemorrhage was found to differ in 0 blood type HD individuals compared to other types. HD males were demonstrated to develop the ruptures of vascular beds significantly more often when compared to HD females (p = 0.0165). Furthermore, 0 blood type HD males were significantly more often affected by a disease manifested with tissue hemorrhage compared to the 0 blood type HD females (p = 0.0081). Collectively, the local status of chronically injured anorectal tissue should be considered when applying surgical techniques. Future studies could include patients with HD grades I and II to gain a comprehensive understanding of the disease progression, allowing for a comparison of tissue changes at different disease stages.
- 4 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 5119
Open AccessEvaluation of Clinical Manifestations of Hemorrhoidal Disease, Carried Out Surgeries and Prolapsed Anorectal Tissues: Associations with ABO Blood Groups of Patients
Hemorrhoidal disease (HD) is a chronic multifactorial disease. Increased abdominal pressure, along with hyperperfusion, neovascularization, overexpression of inflammatory mediators, and dysbiosis, contributes to the development of HD. The deterioration of the anchoring connective tissue with reduced collagen content and altered collagen ratios, dilatation of blood vessels and thrombosis, muscle injury, and inflammation gradually lead to clinically manifesting prolapse and bleeding from hemorrhoids. The associations of the ABO blood types with a disease have been investigated for the upper gastrointestinal tract only. This study aimed to evaluate HD clinical manifestations, surgeries carried out, and the status of prolapsed anorectal tissues by exploring the associations with the patients’ ABO blood groups. Clinical and various morphological methods, combined with extensive bioinformatics, were used. The blood type 0, grade III and IV HD individuals constituted the largest group in a moderately-sized cohort of equally represented males and females studied and submitted to surgical treatment of hemorrhoids. There were significantly more complaints reported by HD females compared to males (p = 0.0094). The Longo technique appeared mostly used, and there were proportionally more surgeries performed below the dentate line for HD individuals with blood type 0 compared to other blood type patients (24% vs. 11%). HD males were found to present with significantly more often inflamed rectal mucosa (p < 0.05). Loosening and weakening of collagenous components of the rectal wall combined with vascular dilation and hemorrhage was found to differ in 0 blood type HD individuals compared to other types. HD males were demonstrated to develop the ruptures of vascular beds significantly more often when compared to HD females (p = 0.0165). Furthermore, 0 blood type HD males were significantly more often affected by a disease manifested with tissue hemorrhage compared to the 0 blood type HD females (p = 0.0081). Collectively, the local status of chronically injured anorectal tissue should be considered when applying surgical techniques. Future studies could include patients with HD grades I and II to gain a comprehensive understanding of the disease progression, allowing for a comparison of tissue changes at different disease stages.
- Open Access
Evaluation and Predictive Factors of Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation Therapy
The response to neoadjuvant chemoradiation therapy is an important prognostic factor for locally advanced rectal cancer. Although the majority of the patients after neoadjuvant therapy are referred to following surgery, the clinical data show that complete clinical or pathological response is found in a significant proportion of the patients. Diagnostic accuracy of confirming the complete response has a crucial role in further management of a rectal cancer patient. As the rate of clinical complete response, unfortunately, is not always consistent with pathological complete response, accurate diagnostic parameters and predictive markers of tumor response may help to guide more personalized treatment strategies and identify potential candidates for nonoperative management more safely. The management of complete response demands interdisciplinary collaboration including oncologists, radiotherapists, radiologists, pathologists, endoscopists and surgeons, because the absence of a multidisciplinary approach may compromise the oncological outcome. Prediction and improvement of rectal cancer response to neoadjuvant therapy is still an active and challenging field of further research. This literature review is summarizing the main, currently known clinical information about the complete response that could be useful in case if encountering such condition in rectal cancer patients after neoadjuvant chemoradiation therapy, using as a source PubMed publications from 2010–2021 matching the search terms “rectal cancer”, “neoadjuvant therapy” and “response”.
Open AccessEvaluation and Predictive Factors of Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation Therapy
The response to neoadjuvant chemoradiation therapy is an important prognostic factor for locally advanced rectal cancer. Although the majority of the patients after neoadjuvant therapy are referred to following surgery, the clinical data show that complete clinical or pathological response is found in a significant proportion of the patients. Diagnostic accuracy of confirming the complete response has a crucial role in further management of a rectal cancer patient. As the rate of clinical complete response, unfortunately, is not always consistent with pathological complete response, accurate diagnostic parameters and predictive markers of tumor response may help to guide more personalized treatment strategies and identify potential candidates for nonoperative management more safely. The management of complete response demands interdisciplinary collaboration including oncologists, radiotherapists, radiologists, pathologists, endoscopists and surgeons, because the absence of a multidisciplinary approach may compromise the oncological outcome. Prediction and improvement of rectal cancer response to neoadjuvant therapy is still an active and challenging field of further research. This literature review is summarizing the main, currently known clinical information about the complete response that could be useful in case if encountering such condition in rectal cancer patients after neoadjuvant chemoradiation therapy, using as a source PubMed publications from 2010–2021 matching the search terms “rectal cancer”, “neoadjuvant therapy” and “response”.
- Open Access
Pathogenic APC Variants in Latvian Familial Adenomatous Polyposis Patients
Background and objectives: Familial adenomatous polyposis is one of the APC-associated polyposis conditions described as genetically predetermined colorectal polyposis syndrome with a variety of symptoms. The purpose of this study was to determine sequence variants of the APC gene in patients with familial adenomatous polyposis (FAP) phenotype and positive or negative family history. Materials and Methods: Eight families with defined criteria of adenomatous polyposis underwent molecular genetic testing. Coding regions and flanking intron regions of the APC gene were analyzed by Sanger sequencing. Results: Eight allelic variants of the APC gene coding sequence were detected. All allelic variants of the APC gene were predicted to be pathogenic based on criteria according to the “Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology” (2015), four of them c.1586_1587insAT, c.2336delT, c.3066_3067insGA, and c.4303_4304insC, were considered novel. Conclusions: The timely molecular genetic analysis of APC germline variants and standardized interpretation of the pathogenicity of novel allelic variants has a high impact on choice for treatment, cancer prevention, and family genetic counseling.
Open AccessPathogenic APC Variants in Latvian Familial Adenomatous Polyposis Patients
Background and objectives: Familial adenomatous polyposis is one of the APC-associated polyposis conditions described as genetically predetermined colorectal polyposis syndrome with a variety of symptoms. The purpose of this study was to determine sequence variants of the APC gene in patients with familial adenomatous polyposis (FAP) phenotype and positive or negative family history. Materials and Methods: Eight families with defined criteria of adenomatous polyposis underwent molecular genetic testing. Coding regions and flanking intron regions of the APC gene were analyzed by Sanger sequencing. Results: Eight allelic variants of the APC gene coding sequence were detected. All allelic variants of the APC gene were predicted to be pathogenic based on criteria according to the “Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology” (2015), four of them c.1586_1587insAT, c.2336delT, c.3066_3067insGA, and c.4303_4304insC, were considered novel. Conclusions: The timely molecular genetic analysis of APC germline variants and standardized interpretation of the pathogenicity of novel allelic variants has a high impact on choice for treatment, cancer prevention, and family genetic counseling.